ADIAL PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK: 0001513525
Period of Report: 2021-11-29

Reporting Person: Stilley William B. III (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-29	Common Stock	P	10000	$2.5892	Acquired	927046	Direct
2021-11-30	Common Stock	P	10600	$2.7527	Acquired	937646	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These 10,000 shares of common stock were purchased in multiple transactions at prices ranging from $2.54 to $2.60, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2: The price reported in Column 4 is a weighted average price. These 10,600 shares of common stock were purchased in multiple transactions at prices ranging from $2.5999 to $2.83, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4